Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)
Recruiting now · Phase 1
Conditions studied: Hepatocellular Carcinoma
In brief
This is a single center, single arm and open-label study to determine the safety of mRNA modified HBV-TCR redirected T-cells and to analyze the changes in tumor microenvironment caused by these HBV-TCR redirected T-cells in subjects with HBV-related HCC who are not amenable to/failed conventional treatment.
Key facts
- Study ID
- NCT04745403
- Run by
- Lion TCR Pte. Ltd.
- People needed
- 10
- Starts
- 2022-05-20
- Expected to finish
- 2028-07-01
- Last updated by the study team
- 2023-11-18
Who can join
Age: 21 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Singapore General Hospital — Singapore, Singapore (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.